Inosine pranobex

Generic Medicine Info
Indications and Dosage
Adjunct in genital warts
Adult: As adjunct to podophyllin or carbon dioxide laser: 1 g tid for 14-28 days.

Subacute sclerosing panencephalitis
Adult: 50-100 mg/kg daily in divided doses 4 hourly. Max: 3-4 g daily.

Mucocutaneous herpes simplex
Adult: 1 g 4 times daily for 7-14 days.
Hypersensitivity. Gout or elevated uric acid blood levels.
Special Precautions
Patient with history of gout or hyperuricaemia, urolithiasis. Renal impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Increased serum and urine uric acid, acute hypersensitivity reactions (e.g. angioedema, anaphylaxis, urticaria).
Gastrointestinal disorders: Constipation, diarrhoea, epigastric discomfort, nausea, vomiting.
General disorders and administration site conditions: Fatigue, malaise.
Musculoskeletal and connective tissue disorders: Arthralgia.
Nervous system disorders: Headache, dizziness, insomnia, nervousness, vertigo.
Renal and urinary disorders: Polyuria.
Skin and subcutaneous tissue disorders: Rash, pruritus.
Monitoring Parameters
Monitor uric acid levels (serum and urine) and renal function during treatment.
Drug Interactions
Increases the plasma concentration of zidovudine.
Mechanism of Action: Inosine pranobex is a purine derivative with antiviral and immunomodulatory properties. It stimulates T-lymphocyte and macrophage cell function and influences cytokine production, thereby normalising the body’s dysfunctional cell-mediated immunity.
Synonym: inosine dimepranol acedoben.
Absorption: Rapidly absorbed from the gastrointestinal tract. Time to peak plasma concentration: 1 hour.
Metabolism: Rapidly metabolised to uric acid; also undergoes oxidation and glucuronidation.
Excretion: Via urine (as metabolites and unchanged drug). Elimination half-life: 50 minutes.
Chemical Structure

Chemical Structure Image
Inosine pranobex

Store at or below 30°C.
MIMS Class
ATC Classification
J05AX05 - inosine pranobex ; Belongs to the class of other antivirals. Used as a direct acting antiviral in the systemic treatment of viral infections.
Anon. Inosine Pranobex. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 11/08/2020.

Buckingham R (ed). Inosine Pranobex. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 11/08/2020.

Imunovir 500 mg Tablets (KoRa Corporation Ltd.). MHRA. Accessed 11/08/2020.

Isoprinosine (Swiss Pharma). MIMS Philippines. Accessed 12/08/2020.

Joint Formulary Committee. Inosine Pranobex. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 11/08/2020.

Disclaimer: This information is independently developed by MIMS based on Inosine pranobex from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
  • Beprin
  • Lanavir
  • Methisoprinol Phapros
  • Methopi
  • Moprin
  • Prinol
  • Tropsine
  • Visoprine
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in